A Phase 1b, Single Arm, Multi-center, Open-label, Dose-escalation Study to Assess the Safety and Efficacy of Intravenous BSG005 in Patients with Invasive Fungal Infection
Latest Information Update: 13 Nov 2024
Price :
$35 *
At a glance
- Drugs BSG 005 (Primary)
- Indications Mycoses
- Focus Adverse reactions
- Sponsors Biosergen
- 13 Nov 2024 New trial record